Health TrialsbyHealthPanel

National Clinical and Biological Sarcoma Database : An Initiative of the French Sarcoma Group

ConditionSarcoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorInstitut Bergonié

About this trial

The BCB SARCOMES database is a clinical and biological national database dedicated to sarcoma that contains 3 main databases with specific aims: the first is the pathology database (French expert network dedicated to the management of bone sarcomas \[RESOS\] / French expert network dedicated to the pathology of sarcomas \[RREPS\]), dedicated to systematic review of mesenchymal tumor diagnostics nationwide; the second is clinical (RESOS / French expert clinical network for sarcomas \[NETSARC\]), collecting multidisciplinary tumor boards (MDTB) data of patients nationwide, and the third (CONTICABASE / BONE / GIST) is dedicated to collecting patients longitudinal/follow up data, with a focus on treatments of every events, and a catalogue of associated samples.

Primary objectives of BCB-SARCOMES are the following: description of the patterns of care and treatment outcomes, assessment of the prognostic factors of patients' outcomes.

With the financial support of the French National Cancer Institute \[Institut National du cancer \[INCa\]).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Diagnosis of sarcoma

Diagnosis in a French Comprehensive Cancer Center

Any age

Disqualifiers

None

Trial population

Diagnosis of sarcoma

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Chemotherapy

    Drug

    treatment as per standard of care

  • Immunotherapeutic Agent

    Drug

    treatment as per standard of care

  • target treatment

    Drug

    treatment as per standard of care

  • Surgery

    Procedure/Surgery

    treatment as per standard of care

  • Radiotherapy

    Radiation

    treatment as per standard of care

Treatment groups

150,000 Participants
are divided into 1 treatment group
Group A: Patients with sarcoma5 interventions

Trial outcomes

Primary outcomes

1

Time to next treatment (TNT)

Time from the systemic treatment onset to the next treatment or death due to any cause, whichever comes first. When neither death nor new systemic therapy is observed, TNT is censored at the date of last patient contact.

Time frame
2 years
2

Time to next treatment (TNT)

Time from the systemic treatment onset to the next treatment or death due to any cause, whichever comes first. When neither death nor new systemic therapy is observed, TNT is censored at the date of last patient contact.

Time frame
5 years
3

Overall survival (OS)

Interval between diagnosis and the time of death. When death is not observed, OS is censored at the date of last patient contact.

Time frame
2 years
4

Overall survival (OS)

Interval between diagnosis and the time of death. When death is not observed, OS is censored at the date of last patient contact.

Time frame
5 years

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Institut Bergonié

Lead sponsor

French Sarcoma Group

Collaborator

Source ClinicalTrials.gov
Apply now